anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
2 g daily in two evenly divided doses. It is advisable to initiate therapy with a lower dosage of sulfasalazine delayed release tablets, e.g., 0.5 to 1.0 g daily, to reduce possible gastrointestinal intolerance. A suggested dosing schedule is given below.

In rheumatoid arthritis, the effect of sulfasalazine delayed release tablets can be assessed by the degree of improvement in the number and extent of actively inflamed joints. A therapeutic response has been observed as early as 4 weeks after starting treatment with sulfasalazine delayed release tablets, but treatment for 12 weeks may be required in some patients before clinical benefit is noted. Consideration can be given to increasing the daily dose of sulfasalazine delayed release tablets to 3 g if the clinical response after 12 weeks is inadequate. Careful monitoring is recommended for doses over 2 g per day.
<P>PROBLEM TO BE SOLVED: To provide a medicine or cosmetic preparation containing a caspase-9 inhibitor which is useable for prophylaxis/treatment of diseases which presence of caspase 9 involves, or suppression of skin cell death by UVB.  <P>SOLUTION: The caspase-9 inhibiting composition comprises one or a plurality of crude medicine extracts selected from the group consisting of a leaf extract of Thea sinensis L. of the family Theaceae, an extract of Potentilla tormentilla Neck. of the family Rosaceae, an extract of Vitis vinifera L. of the family Vitaceae, an extract of Thea sinensis L. of the family Theaceae, an extract of Thea sinensis L. var. assamica Pierre of the family Theaceae, an extract of Aspalathus linearis (N.L.Burm.) R.Dahlgr. of the family Leguminosae, an extract of Tilia cordata Miller of the family Tiliaceae, an extract of Symphytum officinale L. of the family Boraginaceae, an extract of Juliania adstringens of the family Julianiaceae, an aerial part extract of Rumex salicifolius Weinm, a leaf extract of Arctostaphylos patula Greene of the family Ericaceae, a bark extract of Calophyllum brasiliensis Cambess of the family Guttiferae, a bark extract of Schima noronhae Reinw of the family Theaceae, a trunk extract of Grewia salutaris Span of the family Tiliaceae, a trunk or leaf extract of Persea americana Mill of the family Lauraceae, a bark extract of Boswellia serrata of the family Burseraceae, a bark extract of Symplocos racemosa of the family Symplocaceae and a bark extract of Ficus religiosa of the family Moraceae.  <P>COPYRIGHT: (C)2005,JPO&NCIPI
The invention provides and a kind ofly can absorb verifying of material and machine-readable layers for pill, tablet and other. The invention still further relates to the method for the described coating of checking. Described coating is formed by particle grid, and described particle to cause selective diffraction, makes each pill or tablet have optical signature mark through stacking. Can read and verify the described signature being associated with each coating. In one embodiment, described particle is spherical in fact and self-organizing. In one embodiment, form described particle with the material that is conventionally considered to safe GRAS.
Based on the standardized lifestyle intervention, the study subjects in the control group will be treated with CRD. Total daily energy intake will be restricted to 80% of the energy requirement for each age group in the Dietary Reference Intakes of Nutrients for Chinese Residents DRIs 2013. A daily food diary will be kept at least one weekday and one weekend per week.
The safety and efficacy of BLUDIGO were evaluated in a randomized intra-patient controlled, blind to dose of BLUDIGO, multi-center study (NCT04228445) in 118 adult patients undergoing endoscopic urological or gynecological surgical procedures including cystoscopic (58%), robotic (28%), and transvaginal (14%) approaches.

The majority of patients were white (89%), female (74%), and younger than 65 years of age (70%). Mean age was 51 years, and age ranged from 20 to 88 years.

Patients were randomized in a 1:1 ratio to receive 2.5 mL or 5 mL of BLUDIGO intravenously prior to the end of the surgical procedure. Each patient underwent cystoscopy and received 5 mL of sodium chloride injection 0.9% followed by the randomized BLUDIGO dose for visualization of urinary flow from the ureteral orifices. The 2.5 mL dose is not approved [see Dosage and Administration (2.1)].

The ureteral orifices and urine flow were observed and video recorded from 0 to 10 minutes post injection, with separate recordings made following sodium chloride injection and BLUDIGO. The conspicuity of the urine flow from the ureteral orifices was assessed in a randomized, blinded fashion by two independent central reviewers using a 5-point scale (1 = no urine flow observed; 2 = weak urine flow, little color contrast; 3 = Color contrast or significant urine flow; 4 = strong urine flow with good color contrast; and 5 = strong urine flow with striking contrast in color) once after sodium chloride injection and twice after BLUDIGO resulting in paired data. The surgeons also reviewed and scored conspicuity of the urine flow from the ureteral orifices. The responder for a ureter is defined as the difference in conspicuity score between BLUDIGO and sodium chloride injection being at least one point difference and the conspicuity score following BLUDIGO alone being greater than or equal to three. The reviewer agreement with the responder endpoint is acceptable. The proportion of responders along with its 95% confidence interval by ureter and reviewer or surgeon is summarized in Table 3.

  
Table 3. Summary of Proportion of Responders by Ureter and Reviewer or Surgeon in Patients Receiving BLUDIGO 5 mL

*responder: IC conspicuity score ≥ 3 and difference (IC – Saline) in conspicuity score ≥1, missing data is imputed as non-responder

** two-sided 95% confidence limits for the proportion of responder, calculated using the Clopper-Pearson (Exact) method
PROBLEM TO BE SOLVED: To provide an anticancer composition that originates from natural products causing no side effect and drug resistance and can selectively injure malignant cells and is developed from new ideas free from conventional Chinese medicines. SOLUTION: The antitumor composition contains dried Ashitaba (Angelica keiskei) and dried camellia. An additive including dried Ashitaba and dried brown sea weed, when necessary, further dried camellia is added to the feed for poultry. The feed is given to poultry. The whole eggs from the poultry are defatted and dried and the product is used as an antihepatitic composition. In another embodiment, the antitumor composition is obtained by using the whole egg-defatted and dried product, the dried Ashitaba or a combination thereof with camella.
A therapeutic preparation effective against tumours and microbial infections consists of a lysate or lysate fraction of a killed Bacillus subtilis type mesentericus QM-B1585.  The microorganism may be cultured in aerobic submerged culture at 37 DEG  C. in an aqueous medium containing peptone and saccharose.  The bacteria are separated from the medium by (a) centrifugation, (b) filtration or (c) addition of acetone.  The separated bacteria are killed and dehydrated by means of 20 volumes of acetone at -20 DEG  C. followed by ether at -20 DEG  C.  They are then dried.  The dried bacteria are subjected to lysis by treatment with (a) lysozyme in physiological saline at 37 DEG  C. for 35 minutes and then (b) a protease such as trypsin for 1 hour at 37 DEG  C.  An active fraction may be precipitated from the aqueous lysate by addition of (a) a copper salt such as CuSo4, (b) acetone or (c) cetyl trimethyl ammonium bromide.  The copper ions are removed from the copper complex by adsorption on a strong cation-exchange resin. The preparation is administered as the active fraction of the lysate, the aqueous lysate or the dried lysate.
Risk of Hepatotoxicity [see Warnings and Precautions (5.1)]

  * JUXTAPID can cause both elevations in transaminases and hepatic steatosis. Discuss with the patient the importance of monitoring of liver-related tests before taking JUXTAPID, prior to each dose escalation, and periodically thereafter.
  * Patients should be advised of the potential for increased risk of liver injury if alcohol is consumed while taking JUXTAPID. It is recommended that patients taking JUXTAPID limit consumption to not more than one alcoholic drink per day.
  * JUXTAPID is commonly associated with nausea, vomiting, and abdominal pain. Advise patients to promptly report these symptoms if they increase in severity, persist, or change in the character, as they might reflect liver injury. Patients should also report any other symptoms of possible liver injury, including fever, jaundice, lethargy, or flu-like symptoms.
In VA, patient-aligned care teams (PACTs) or primary care is step 1 of VA's Stepped Care Model in the treatment of chronic pain. PCPs are expected to possess the requisite skill set for management of common chronic pain-causing conditions, which includes biopsychosocial assessment, multi-modal treatment, and coordination of specialty pain care after shared-decision making that incorporates patient preferences and values. Participants randomized to this arm will continue to have their PCP and PACT serve in this role.
PURPOSE:To enhance the stability of an emulsion by emulsifying an oily substance by a reactive surfactant having polymerization properties and subsequently polymerizing the surfactant locally adsorbed on the interface parts of emulsion liquid droplets to coat the interface parts with an ultra-thin polymer film. CONSTITUTION:As a reactive surfactant, one having one or more of a vinyl group and a methacrylic group and forming a high molecular ultra-thin film by polymerization and insoluble in water or oil after the completion of polymerization is used. Especially, a difunctional surfactant capable of forming a crosslinkable film is pref. At first, oil to be emulsified is mixed with the surfactant to be uniformly emulsified by a high speed mixer. Next, a polymerization initiator such as potassium persulfate is added to the emulsion to be mixed therewith in a nitrogen gas stream to perform polymerization. As the polymerization initiator, an oil-soluble one such as benzoyl peroxide can be also used. The polymerization due to ultraviolet rays is also effective. By this method, the stability of an emulsion is enhanced.
Irritable bowel syndrome (IBS) is a common functional gastrointestinal disorder characterized primarily by abdominal pain associated with bowel dysfunction. Like many other painful functional somatic syndromes (e.g. fibromyalgia) the pathophysiology of IBS includes abnormal responses to pain and dysregulation of brain-body pain pathways. IBS affects up to 10% of the population, is a leading reason for visits to gastroenterologists and primary care doctors, and, in the United States, annually accrues health care costs over $20 billion.

In their practice the investigators use centrally acting agents to treat IBS. Historically, the investigators have used tricyclic antidepressants based on results of clinical trials, including our NIH funded trial on desipramine. Nonetheless, these agents can produce side effects that limit their full application. More recently the investigators have begun to use SNRIs because they have been shown to benefit for various pain syndromes like diabetic neuropathy, fibromyalgia. The initial impression is that Milnacipran helps improve IBS symptoms and global well being. There is now a need to systematically determine Milnacipran's value for IBS.
There are significant racial disparities in obesity and diabetes such that prevalence rates are higher among Black Americans than White Americans. This study examined effects of communicating the prevalence of obesity/diabetes and comparing race-specific prevalence rates between White and Black Americans to highlight racial health disparities. We conducted two preregistered, between-subjects randomized online experiments with an analytic sample of 1,232 U.S. adults (n = 609 for the obesity study and n = 623 for the diabetes study) stratified by race. In each experiment, we randomly assigned respondents to read an obesity/diabetes message 1) without disease prevalence information, 2) with the national obesity/diabetes prevalence rate, 3) with the race-specific obesity/diabetes prevalence rate among White Americans, 4) with the race-specific prevalence rate among Black Americans, or 5) comparing the race-specific prevalence rates between White and Black Americans, or 6) to a no-message condition. Results showed that diabetes prevalence information reduced the overestimation of race-specific diabetes prevalence. Comparing the obesity prevalence rate among White Americans to that of Black Americans increased support for policies to reduce racial health disparities, but also made Black respondents less likely to cut calories. Race-specific disease prevalence information and intergroup disease prevalence comparisons may have both positive and unintended consequences on message recipients. Health educators should be more cautious when communicating disease prevalence information.
Low exercise capacity is an early clinical marker of metabolic impairment that predicts type 2 diabetes (T2D) risk, as well as future co-morbidities and complications. Aerobic exercise training is the only effective treatment to increase exercise capacity and reduce metabolic risk. However, despite maintaining similar levels of physical activity, exercise capacity remains lower in people with impaired glucose tolerance and T2D, compared to those with normal glucose tolerance, suggesting "exercise resistance". The mechanisms of exercise resistance in metabolic disease are unknown. In preclinical studies, exercise-induced increases in circulating angiogenic markers and skeletal muscle capillary density predict improved exercise capacity with training. Furthermore, it was demonstrated that impaired glucose tolerance precedes exercise resistance and impaired exercise-induce angiogenesis in muscle. Based on these data, it was hypothesized that exercise resistance in human T2D is caused by an impaired angiogenic response to exercise, secondary to impaired glycemic control. This study will determine whether the angiogenic response to a single bout of exercise in human subjects is blunted in patients with impaired glucose tolerance (IGT), compared to those with normal glucose tolerance (NGT). Angiogenic potential will be measured using a novel in vitro assay developed to assess endothelial tube-formation induced by circulating serum angiogenic regulators following exercise. In addition, a novel exercise-activated signaling pathway in skeletal muscle that is predictive of exercise resistance in animal models was identified. A second aim of the proposed investigation is to determine the effect of impaired glucose tolerance on molecular signaling in response to exercise in skeletal muscle. This investigation represents a critical step in determining the mechanisms that contribute to low exercise capacity in individuals at risk for diabetes.
Post-stroke hand impairment is highly prevalent and severely restricts functional ability and independence. Yet, there is no assistive device to help hand function at home, every day, during activities of daily living. Existing devices such as hand-opening orthoses are expensive, uncomfortable, bulky, and meant for use during short therapy sessions as opposed to during daily living. Thus their impact is limited. Consequently, the development of efficacious and affordable assistive device is of importance. This project addresses this critical gap by providing an innovative patent-pending technology. The "TheraBracelet" is a wristband applying imperceptible vibration to skin. TheraBracelet is efficacious, as it has been shown to immediately improve chronic stroke survivors' touch sensation and hand dexterity in previous studies. TheraBracelet is affordable by using only a low-cost vibrator. TheraBracelet is also translational, because a vibrator strategically placed at the wrist does not interfere with dexterous finger motions, and it is low-risk by involving only imperceptible vibration on skin. These practicalities assure easy adoption in home environment for large impact on sensorimotor impairment. The essential next step, thus the objective of this Phase I project, is to determine the feasibility and safety of using this assistive device all day every day for a month during daily activity. This objective will be accomplished in a double-blinded, randomized, controlled, crossover design study. Feasibility (compliance of using the device everyday) and safety will be assessed for the real vibration condition compared to the sham vibration condition (wearing the device without vibration). The feasibility and safety level comparable to those of wearing a watch and of a comparable FDA-approved device will support viability of TheraBracelet with necessary regulatory approvals. This project is expected to lead to an assistive wristband that increases hand function during activities of daily living for a large number of stroke survivors with hand impairment.
BACKGROUND/AIM: The serine proteinase inhibitor 1 (SERPINE1) gene codes for the plasminogen activator inhibitor 1 (PAI1) protein and is thought to play a tumor supportive role in various cancers. In this work we aimed to uncover the role PAI1 plays in the proliferation, migration, and invasion of vulvar cancer (VC), and define the protein's function as an oncogene or tumor suppressor.
MATERIALS AND METHODS: Through treatment with an agonist (G1) and antagonist (G36) of G-coupled estrogen receptor 1 (GPER1), an upstream regulator of SERPINE1 expression, and a forward transfection knockdown protocol, the expression of SERPINE1/PAI1 in VC cells was altered. The effects these altered SERPINE1/PAI1 levels had on tumor cell functions were then examined. Proliferation was analyzed using the resazurin assay, while migration was studied via the gap closure assay. Through colony- and tumor sphere- formation assays clonogenicity was tested, and western blots showed protein expression.
RESULTS: In A431 VC cells, when the levels of PAI1 were reduced via knockdown or treatment with G1, migration, proliferation, and colony growth was reduced. Treatment with G36 increased expression of PAI1 and increased migration and colony size in CAL39 cells.
CONCLUSION: Based on the findings in this study, suppressing PAI1 expression in VC cells appears to reduce their progression and tumorigenic potential. Therefore, PAI1 could possibly function as an oncogene in VC. GPER1 appears to be a suitable target for suppressing PAI1 in VC.
For the purpose of cervical ripening none procedure will be performed to Group 1, while vaginal misoprostole of 200 mg and vaginal dinoprostone will be applied to Group 2 and 3, respectively. While misoprostol will be implanted 3 hours before procedure, but dinoprostone will be implanted 6 hours before procedure. Before drug implantation for determination of the cervical insufficiency and measure of the cervical canal's opening, bougies will be applied toward to back from 8 no- hegar bougie.
In an embodiment, a control system (100) is described. The control system controls a respiratory support system (102) for supplying a therapeutic gas to a subject (104). The control system includes processing circuitry (106) communicatively coupled to the interface (108) for receiving an indication of a combination of head orientation and torso orientation of the subject. The indication is based on orientation data provided by a sensing system (216) configured to detect a head orientation and a torso orientation of the subject. The control system further includes a machine readable medium (110) storing instructions (112). The instructions, when executed by the processing circuitry, cause the processing circuitry to identify parameter values of the therapeutic gas from parameter information associated with each of a set of different combinations of head orientation and torso orientation for use by the respiratory support system in supplying (114) the therapeutic gas to the subject for the indicated combination of head orientation and torso orientation of the subject. The respiratory support system is caused to supply a therapeutic gas having the identified parameter value.
Food hydrolysate instilled into terminal cecum of patient undergoing open duodenal switch procedure. Blood samples were then obtained at baseline and at 0, 30, 60, 90, and 120 minutes for analysis of circulating GLP-1, PYY, and leptin.
Apparatus and methods are described including, using a computer processor ( 28 ), automatically identifying whether a given pixel ( 111 ) within an image corresponds to a portion of an object. A set of concentric circles ( 132   a - c ) that are disposed around the pixel are sampled, and a first function is applied to each of the circles such that the circles are defined by a first set of rotationally invariant descriptors. A second function is applied to the set of circles to generate a second set of descriptors, each of which represents a difference between respective pairs of the circles. A third function is applied such that the second set of descriptors becomes rotationally invariant. The processor identifies whether the given pixel corresponds to the portion of the object, based upon the first and second sets of rotationally invariant descriptors. Other applications are also described.
INTRODUCTION: An optimal follow-up schedule for small (≤3-cm) hepatocellular carcinoma (HCC) after radiofrequency ablation (RFA) remains unclear in clinical guidelines. We aimed to assess the cost-effectiveness of follow-up strategies in patients with small HCC after RFA.
METHODS: In total, 11,243 patients were collected from global institutions to calculate recurrence rates. Subsequently, a Markov model covering a 10-year period was developed to compare 25 surveillance strategies involving different surveillance techniques (computed tomography [CT], magnetic resonance imaging or ultrasonography [US], and α-fetoprotein [AFP]) and intervals (3 or 6 months). The study endpoint was incremental cost-effectiveness ratio (ICER), which represented additional cost per incremental quality-adjusted life year. Sensitivity analysis was conducted by varying the values of input parameters to observe the ICER.
RESULTS: In a base case analysis, the dominant strategy was CT every 3 months during an initial 2 years, followed by semiannual CT, and then switch to biannual the combination of US screening and AFP testing after 5 years (m3_CT-m6_CT-m6_USAFP), with an ICER of $68,570.92 compared with the "not followed" strategy. One-way sensitivity analysis showed the ICER consistently remained below the willingness-to-pay threshold of $100,000.00. In a probabilistic sensitivity analysis, m3_CT-m6_CT-m6_USAFP was the most cost-effective approach in 95.6% of simulated scenarios at a willingness-to-pay threshold.
DISCUSSION: For small HCC after RFA, the recommended follow-up strategy is CT, with scans scheduled every 3 months for the first 2 years, every 6 months thereafter, and transition to biannual the combination of US screening and AFP testing after 5 years.